Absconding among admitted patients with bipolar affective disorder diagnosis in Uganda.

Publisher: BioMed Central Country of Publication: England NLM ID: 100968559 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-244X (Electronic) Linking ISSN: 1471244X NLM ISO Abbreviation: BMC Psychiatry Subsets: MEDLINE

Original Publication: London : BioMed Central, [2001-

Bipolar Disorder*/complications ; Bipolar Disorder*/diagnosis ; Bipolar Disorder*/epidemiology; Humans ; Retrospective Studies ; Haloperidol ; Uganda/epidemiology ; Patient Dropouts/psychology ; Hospitalization ; Mood Disorders/complications ; Mood Disorders/diagnosis ; Mood Disorders/epidemiology

Background: Hospitalization is often necessary for individuals with Bipolar affective Disorder (BAD) during severe manic or depressive episodes, as well as for stabilizing treatment regimens. However, a significant proportion of patients admitted for treatment of BAD abscond or leave the hospital without permission during their stay. In addition, patients managed for BAD may have unique characteristics that might force them into absconding. For example, the high prevalence of co-morbid substance use disorder - craving to use substances, suicidal behaviors - attempts to die by suicide, and cluster B personality disorders - characterized by impulsive acts. It is, therefore, essential to understand the factors contributing to absconding among patients with BAD, to facilitate designing strategies for preventing and managing this behavior.
Method: This study was based on a retrospective chart review of the inpatients diagnosed with BAD at a tertiary psychiatry facility in Uganda from January 2018 to December 2021.
Results: Approximately 7.8% of those with BAD absconded from the hospital. The likelihood of absconding among those with BAD increased with the use of cannabis [adjusted odds ratio (aOR) = 4.00, 95% confidence interval (CI) = 1.22-13.09, p-value = 0.022] and having mood lability [aOR = 2.15, 95% CI = 1.10-4.21, p-value = 0.025]. However, receiving psychotherapy during the admission (aOR = 0.44, 95 CI = 0.26-0.74, p-value = 0.002) and treatment with haloperidol (aOR = 0.39, 95% CI = 0.18-0.83, p-value = 0.014) reduced the likelihood of absconding.
Conclusion: Absconding among patients with BAD is common in Uganda. Those with symptoms of affective lability and those with comorbid cannabis use tend to abscond more, while those who receive haloperidol and psychotherapy are less likely to abscond.
(© 2023. The Author(s).)

Expert Rev Neurother. 2022 Nov-Dec;22(11-12):995-1008. (PMID: 36573268)
Br J Psychiatry. 2004 Jul;185:63-9. (PMID: 15231557)
J Adv Nurs. 2000 Sep;32(3):644-9. (PMID: 11012807)
Am J Addict. 2020 Jan;29(1):9-26. (PMID: 31577377)
J Affect Disord. 2015 Jan 15;171:39-47. (PMID: 25285897)
PLoS One. 2015 Sep 24;10(9):e0138819. (PMID: 26401653)
BMJ. 2007 Oct 27;335(7625):865. (PMID: 17954514)
Bipolar Disord. 2009 Dec;11(8):787-806. (PMID: 19922550)
J Psychiatr Ment Health Nurs. 2009 Mar;16(2):153-7. (PMID: 19281546)
J Clin Nurs. 2011 Mar;20(5-6):706-13. (PMID: 21320199)
J Psychiatr Res. 2019 Apr;111:134-139. (PMID: 30738930)
Psychiatr Q. 2020 Jun;91(2):299-307. (PMID: 31898213)
S Afr J Psychiatr. 2019 Dec 04;25:1338. (PMID: 31850152)
Lancet Psychiatry. 2016 Sep;3(9):842-9. (PMID: 27477886)
Crim Behav Ment Health. 2002;12(4):244-53. (PMID: 12897900)
J Clin Nurs. 2015 Mar;24(5-6):855-65. (PMID: 25209549)
J Clin Psychol. 2007 May;63(5):417-24. (PMID: 17417809)
Br J Psychiatry. 1989 Mar;154:368-71. (PMID: 2597839)
Neuropsychopharmacology. 2014 Aug;39(9):2041-8. (PMID: 24633558)
BMC Psychiatry. 2010 Feb 03;10:14. (PMID: 20128891)
BMC Psychiatry. 2014 Mar 27;14:91. (PMID: 24669758)
Ther Adv Psychopharmacol. 2011 Dec;1(6):197-204. (PMID: 23983947)
Med Clin North Am. 2001 May;85(3):617-29. (PMID: 11349476)
Psychol Med. 2017 Apr;47(5):902-912. (PMID: 27894372)
Aust N Z J Psychiatry. 2008 Apr;42(4):267-82. (PMID: 18330769)
BMC Psychiatry. 2021 Mar 4;21(1):122. (PMID: 33663445)
J Nerv Ment Dis. 2009 Jan;197(1):35-40. (PMID: 19155808)
BMC Psychiatry. 2021 Jul 26;21(1):371. (PMID: 34311731)
Can Psychiatr Assoc J. 1975 Oct;20(6):429-34. (PMID: 1192328)
Depress Anxiety. 2016 Jan;33(1):45-55. (PMID: 26350166)
Front Neurosci. 2018 Oct 22;12:730. (PMID: 30405331)
Med Glas (Zenica). 2012 Aug;9(2):345-9. (PMID: 22926375)
PLoS One. 2022 May 26;17(5):e0269044. (PMID: 35617261)
Emotion. 2006 May;6(2):239-45. (PMID: 16768556)
J Head Trauma Rehabil. 2005 Jul-Aug;20(4):377-88. (PMID: 16030444)
Psychiatr Serv. 2002 Oct;53(10):1272-84. (PMID: 12364675)
Acta Psychiatr Scand. 2013 Sep;128(3):149-62. (PMID: 23617548)
Acta Psychiatr Scand Suppl. 2007;(434):41-9. (PMID: 17688462)
Bipolar Disord. 2000 Sep;2(3 Pt 2):269-80. (PMID: 11249805)
J Psychiatr Ment Health Nurs. 2008 Aug;15(6):458-64. (PMID: 18638205)
J Trauma Dissociation. 2010;11(2):228-43. (PMID: 20373208)
Risk Manag Healthc Policy. 2022 Apr 19;15:703-711. (PMID: 35469181)
Br J Pharmacol. 2022 Sep;179(17):4201-4219. (PMID: 33830495)

Keywords: Absconding; Bipolar affective disorder; Haloperidol; Mood lability; Psychotherapy; cannabis

J6292F8L3D (Haloperidol)

Date Created: 20230504 Date Completed: 20230508 Latest Revision: 20230512

20240829

PMC10161627

10.1186/s12888-023-04794-w

37142973